Recombinant Human VEGFR2/Flk-1/KDR Protein (Fc Tag)
Recombinant Human VEGFR2/Flk-1/KDR Protein (Fc Tag) supplied by Elabscience with collaborator-provided technical specifications. Read more ›
["1. Immobilized recombinant human VEGFA at 1. 25 μg/ml (100 μl/well) can bind VEGFR2 with a linear range of 1.25-40.0 ng/ml. 2. Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 20-120 ng/mL in the presence of 10 ng/mL recombinant human VEGF165. ,150-160 kDa"]Product Description
VEGFR2/Flk-1/KDR is the stated recombinant protein target for this Elabscience product. The listing uses collaborator-supplied specifications to support research-use-only protein selection through ABMIUM.
Protein profile: reactive species/source: Human; expression system: HEK293 Cells; physical form: Lyophilized from sterile PBS, pH 7.4<br/>Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.<br/>Please refer to the specific buffer information in the printed manual.; tag: Human ,VEGFR2/Flk-1/KDR ,Cytokines; predicted molecular weight: 109 kDa.
Quality and formulation: purity: > 90 % as determined by reducing SDS-PAGE.; endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method..
Functional evidence: activity: 1. Immobilized recombinant human VEGFA at 1. 25 μg/ml (100 μl/well) can bind VEGFR2 with a linear range of 1.25-40.0 ng/ml. 2. Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC). The ED<sub>50</sub> for this effect is typically 20-120 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.. In the ABMIUM matrix, collaborator-supplied functional evidence is marked C; unsupported application columns remain N.
Sequence coverage: 109 kDa.
Database references: UniProt: NP_002244.1 | Gene symbol: VEGFR2/Flk-1/KDR.
Research Use Only.
Key Facts
| Target | VEGFR2/Flk-1/KDR |
| Also known as | CD309, FLK-1, FLK1, Fetal liver kinase 1, Flk-1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2 |
| Species reactivity | Human |
| Purity | > 90 % as determined by reducing SDS-PAGE. |
| Form / buffer | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Shelf life | 12 months |
| Research area | Signal Transduction, Microbiology, Cardiovascular, Cancer, metabolism, Stem cells |
| BIOACTIVITY | BINDING | CELL-BASED | IN VIVO | ELISA CAPTURE | |
|---|---|---|---|---|---|
| Human |
Specifications
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Storage & Stability
Compliance & Certifications
Manufactured under ISO 9001:2015 quality management standards.
Manufactured under ISO 14001:2015 quality management standards.
Manufactured under ISO 45001:2018 quality management standards.
Not intended for diagnostic or therapeutic use.
Substance does not appear on the SVHC candidate list.